Aurora Cannabis Inc. (ACB)
Pre-market:
| Previous close | 6.32 |
| Open | 6.32 |
| Bid | 9.26 x 100 |
| Ask | 10.52 x 100 |
| Day's range | 6.18 - 9.35 |
| 52-week range | 2.84 - 11.50 |
| Volume | |
| Avg. volume | 6,987,211 |
| Market cap | 504.783M |
| Beta (5Y monthly) | 2.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -57.99 |
| Earnings date | 12 June 2024 - 17 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.10 |
ZacksAurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?
Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PR NewswireAurora Improves Offerings in Australia with New Range of Premium Dried Flower Products
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is pleased to announce the expansion of its portfolio with the introduction of a new range of premium dried cannabis flower products. Now available for doctors to prescribe to patients in Australia, the new products developed by Aurora and manufactured at its EU-GMP and TGA-GMP certified facility, will be distributed by MedReleaf Australia, a premie
ZacksHas Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
